Core One Labs awaits patent for cost-effective biosynthetic psilocybin production system
Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
Vocan Biotechnologies Inc., a subsidiary of Core One Labs Inc. (COOL) is days away from receiving a patent for its biosynthetic psilocybin production system, which is more efficient and significantly cheaper than conventional methods of extracting psilocybin. The proprietary system aims to produce a reliable product that is consistent in quality and concentration while remaining comparable to naturally occurring psilocybin. Core One believes that there is a wide appeal for biosynthetic production as the psychedelics market grows, as “the need for a steady and consistent supply chain will also increase”.
Core One Labs has initiated the development of patent-pending drug formulation that uses psilocybin to treat the underlying cause of Alzheimer’s Disease
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
Akome Biotech Ltd., a subsidiary of Core One Labs Inc. (COOL), has initiated the development of patent-pending drug formulation made of psilocybin and a plant bioactive compound, which is believed to help treat Alzheimer’s Disease. While current Alzheimer’s treatments focus on treating symptoms of the disease, the new drug formulation known as AKO002 aims to treat the underlying cause of the disease by targeting serotonin receptors in the hippocampus. Data mapping reveals that psychedelics like psilocybin have “positive effects in the promotion of neuroplasticity and neurogenesis” and have “potent anti-inflammatory properties”.